Zoetis Inc. – LSE:0M3Q.L
Zoetis stock price today
Zoetis stock price monthly change
Zoetis stock price quarterly change
Zoetis stock price yearly change
Zoetis key metrics
Market Cap | 74.36B |
Enterprise value | 79.30B |
P/E | 30.67 |
EV/Sales | 8.66 |
EV/EBITDA | 20.59 |
Price/Sales | 8.11 |
Price/Book | 14.24 |
PEG ratio | 1.56 |
EPS | 5.19 |
Revenue | 8.73B |
EBITDA | 3.56B |
Income | 2.39B |
Revenue Q/Q | 9.5% |
Revenue Y/Y | 7.90% |
Profit margin | 26.55% |
Oper. margin | 36.45% |
Gross margin | 68.87% |
EBIT margin | 36.45% |
EBITDA margin | 40.84% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeZoetis stock price history
Zoetis stock forecast
Zoetis financial statements
| Jun 2023 | 2.18B | 671M | 30.78% |
|---|---|---|---|
| Sep 2023 | 2.15B | 596M | 27.71% |
| Dec 2023 | 2.21B | 525M | 23.72% |
| Mar 2024 | 2.19B | 599M | 27.35% |
| Sep 2025 | 2.45B | 754.32M | 30.67% |
|---|---|---|---|
| Oct 2025 | 2.43B | 744.40M | 30.52% |
| Dec 2025 | 2.48B | 717.32M | 28.82% |
| Mar 2026 | 2.42B | 726.95M | 30.04% |
Analysts Price target
Financials & Ratios estimates
| Payout ratio | 31.44% |
|---|
| 2019 | 0.5% |
|---|---|
| 2020 | 0.48% |
| 2021 | 0.41% |
| 2022 | 0.89% |
| 2023 | 0.76% |
| Jun 2023 | 13749000000 | 9.12B | 66.39% |
|---|---|---|---|
| Sep 2023 | 14106000000 | 9.03B | 64.03% |
| Dec 2023 | 14286000000 | 9.29B | 65.06% |
| Mar 2024 | 14348000000 | 9.29B | 64.79% |
| Jun 2023 | 183M | -80M | -494M |
|---|---|---|---|
| Sep 2023 | 724M | -271M | -416M |
| Dec 2023 | 897M | -210M | -397M |
| Mar 2024 | 595M | -131M | -524M |
Zoetis alternative data
| Aug 2023 | 13,800 |
|---|---|
| Sep 2023 | 13,800 |
| Oct 2023 | 13,800 |
| Nov 2023 | 13,800 |
| Dec 2023 | 13,800 |
| Jan 2024 | 13,800 |
| Feb 2024 | 13,800 |
| Mar 2024 | 14,100 |
| Apr 2024 | 14,100 |
| May 2024 | 14,100 |
| Jun 2024 | 14,100 |
| Jul 2024 | 14,100 |
Zoetis other data
| Insider | Compensation |
|---|---|
Mr. Juan RamĂłn Alaix (1951) Advisor & Director | $3,420,000 |
| Ms. Kristin C. Peck (1971) Chief Executive Officer & Director | $1,530,000 |
Mr. Glenn C. David (1972) Executive Vice President & Chief Financial Officer | $1,520,000 |
| Dr. Catherine A. Knupp (1961) Executive Vice President and Pres of R&D | $1,510,000 |
| Mr. Roman Trawicki Executive Vice President and Pres of Global Manufacturing & Supply | |
| Ms. Wafaa Mamilli Executive Vice President and Chief Information & Digital Officer | |
| Ms. Heidi C. Chen Executive Vice President, Gen. Counsel & Corporation Sec. | |
| Ms. Roxanne Lagano Executive Vice President and Chief HR Officer & Global Operations | |
Mr. Steven Frank Vice President of Investor Relations | |
Mr. William Price Vice President & Chief Communications Officer |
-
What's the price of Zoetis stock today?
One share of Zoetis stock can currently be purchased for approximately $234.02.
-
When is Zoetis's next earnings date?
Unfortunately, Zoetis's (0M3Q.L) next earnings date is currently unknown.
-
Does Zoetis pay dividends?
Yes, Zoetis pays dividends and its trailing 12-month yield is 1.05% with 31% payout ratio. The last Zoetis stock dividend of $0.2 was paid on 1 Sep 2020.
-
How much money does Zoetis make?
Zoetis has a market capitalization of 74.36B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 5.74% to 8.54B US dollars.
-
What is Zoetis's stock symbol?
Zoetis Inc. is traded on the LSE under the ticker symbol "0M3Q.L".
-
What is Zoetis's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Zoetis?
Shares of Zoetis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Zoetis's key executives?
Zoetis's management team includes the following people:
- Mr. Juan RamĂłn Alaix Advisor & Director(age: 74, pay: $3,420,000)
- Ms. Kristin C. Peck Chief Executive Officer & Director(age: 54, pay: $1,530,000)
- Mr. Glenn C. David Executive Vice President & Chief Financial Officer(age: 53, pay: $1,520,000)
- Dr. Catherine A. Knupp Executive Vice President and Pres of R&D(age: 64, pay: $1,510,000)
- Mr. Roman Trawicki Executive Vice President and Pres of Global Manufacturing & Supply
- Ms. Wafaa Mamilli Executive Vice President and Chief Information & Digital Officer
- Ms. Heidi C. Chen Executive Vice President, Gen. Counsel & Corporation Sec.
- Ms. Roxanne Lagano Executive Vice President and Chief HR Officer & Global Operations
- Mr. Steven Frank Vice President of Investor Relations
- Mr. William Price Vice President & Chief Communications Officer
-
How many employees does Zoetis have?
As Jul 2024, Zoetis employs 14,100 workers.
-
When Zoetis went public?
Zoetis Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is Zoetis's official website?
The official website for Zoetis is zoetis.com.
-
Where are Zoetis's headquarters?
Zoetis is headquartered at 10 Sylvan Way, Parsippany, NJ.
-
How can i contact Zoetis?
Zoetis's mailing address is 10 Sylvan Way, Parsippany, NJ and company can be reached via phone at +973 8227000.
Zoetis company profile:
Zoetis Inc.
zoetis.comLSE
14,100
Medical - Pharmaceuticals
Healthcare
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Parsippany, NJ 07054
:
ISIN: US98978V1035
:
